UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
52643,EuroNext,NewsApi.org,https://biztoc.com/x/0c56ff5b7e666851,Stifel expands execution services team with Euronext hire,Stifel has made an addition to its execution services team  appointing Matthew McNestry as managing director in low-touch trading  The TRADE can reveal. London-based McNestry brings more than 20 years of industry experience spanning electronic trading  portf…,Stifel has made an addition to its execution services team  appointing Matthew McNestry as managing director in low-touch trading  The TRADE can reveal.London-based McNestry brings more than 20 years of industry experience spanning electronic trading  portfolio trading and sales to his…This story appeared on thetradenews.com   2025-09-02 10:16:33.,neutral,0.01,0.99,0.0,neutral,0.02,0.98,0.0,True,English,"['execution services team', 'Stifel', 'Euronext', 'execution services team', 'Matthew McNestry', 'managing director', 'low-touch trading', 'The TRADE', 'London-based McNestry', 'industry experience', 'electronic trading', 'portfolio trading', 'Stifel', 'addition', '20 years', 'sales', 'story', 'thetradenews.']",2025-09-02,2025-09-03,biztoc.com
52644,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2025/09/02/3142334/0/en/Cegedim-shares-transferred-to-trading-on-Euronext-Growth-as-of-September-4-2025.html,Cegedim: shares transferred to trading on Euronext Growth as of September 4  2025,PRESS RELEASE Share listing information   Cegedim Group shares transferred to trading on Euronext Growth as of September 4  2025 ...,PRESS RELEASEShare listing informationCegedim Group shares transferred to trading on Euronext Growth as of September 4  2025Boulogne-Billancourt  September 2  2025 – Cegedim  an innovative technology and services company  announces that trading in its shares is being transferred from the regulated market of Euronext Paris (compartment B) to Euronext Growth Paris  effective September 4  2025.The Euronext admission committee approved the application to admit CEGEDIM S.A. shares to Euronext Growth Paris on August 29  2025.The transfer was authorized by the General Shareholders’ Meeting of June 13  2025  and initiated by the Group’s Board of Directors. It will raise the profile and enhance the appeal of the share and will also entail some regulatory relief.Even so  the Group will maintain its current level of financial communication. Cegedim will continue to publish quarterly revenue figures  consolidated financial statements that adhere to IFRS  and CSRD-compliant sustainability reporting—the change in market listing will have no impact in this regard.For the Prospectus detailing the listing transfer to Euronext Growth Paris  please visit the “Finance” section of our website: https://www.cegedim.com.The ISIN code for CEGEDIM S.A. shares is unchanged: FR0000053506.The ticker symbol will change to ALCGM on September 4  2025.TP ICAP  acting as Listing Sponsor  has assisted CEGEDIM S.A. with the transfer to Euronext Growth Paris.Definitive transfer timelineAugust 29  2025: Euronext announces its decision to admit CEGEDIM S.A. shares to trading on Euronext Growth Paris.September 2  2025: Group press release announces its listing transfer  and Prospectus posted on the Cegedim and Euronext websites.September 2  2025: Euronext market notice announces the removal of CEGEDIM S.A. common shares from Euronext Paris.September 2  2025: Euronext market notice announces the admission of CEGEDIM S.A. common shares (ALCGM) to Euronext Growth Paris.September 4  2025: Transfer takes effect—CEGEDIM S.A. shares removed from Euronext Paris (before trading opens) and admitted to Euronext Growth Paris (when trading opens)  initial listing.About Cegedim:Founded in 1969  Cegedim is an innovative technology and services group in the field of digital data flow management for healthcare ecosystems and B2B  and a business software publisher for healthcare and insurance professionals. Cegedim employs nearly 6 700 people in more than ten countries and generated revenue of over €654 million in 2024.Cegedim SA is listed in Paris (EURONEXT: CGM).To learn more please visit: www.cegedim.frAnd follow Cegedim on X: @CegedimGroup  LinkedIn  and Facebook.Aude BalleydierCegedimMedia Relations and Communications ManagerTel.: +33 (0)1 49 09 68 81aude.balleydier@cegedim.fr Damien BuffetCegedimHead of FinancialCommunicationTel.: +33 (0)7 64 63 55 73damien.buffet@cegedim.com Céline PardoBecoming RP AgencyMedia Relations ConsultantTel.: +33 (0)6 52 08 13 66cegedim@becoming-group.comAttachment,neutral,0.0,0.99,0.0,neutral,0.06,0.93,0.01,True,English,"['Euronext Growth', 'Cegedim', 'shares', 'September', 'RP Agency Media Relations Consultant', 'CEGEDIM S.A. common shares', 'digital data flow management', 'CEGEDIM S.A. shares', 'The Euronext admission committee', 'General Shareholders’ Meeting', 'CSRD-compliant sustainability reporting', 'business software publisher', 'Céline Pardo', 'consolidated financial statements', 'Euronext market notice', 'quarterly revenue figures', 'Euronext Growth Paris', 'Cegedim Group shares', 'Definitive transfer timeline', 'Share listing information', 'Group press release', 'Euronext Paris', 'market listing', 'Euronext websites', 'regulated market', 'financial communication', 'Listing Sponsor', 'initial listing', 'Cegedim SA', 'innovative technology', 'services company', 'compartment B', 'regulatory relief', 'current level', 'Finance” section', 'ISIN code', 'ticker symbol', 'TP ICAP', 'insurance professionals', 'ten countries', 'Communications Manager', 'listing transfer', 'services group', 'healthcare ecosystems', 'Aude Balleydier', 'Damien Buffet', 'September', 'Boulogne-Billancourt', 'trading', 'application', 'August', 'June', 'Board', 'Directors', 'profile', 'appeal', 'IFRS', 'change', 'impact', 'regard', 'Prospectus', 'ALCGM', 'decision', 'removal', 'effect', 'field', 'B2B', '6,700 people', 'CegedimGroup', 'LinkedIn', 'Facebook', 'Tel.', 'Head', 'Attachment', '1 49']",2025-09-02,2025-09-03,globenewswire.com
52645,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2025/09/02/3142312/0/en/Pharming-Group-appoints-Kenneth-Lynard-as-Chief-Financial-Officer.html,Pharming Group appoints Kenneth Lynard as Chief Financial Officer,Leiden  the Netherlands  September 2  2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO)  effective October 1  2025.,Leiden  the Netherlands  September 2  2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO)  effective October 1  2025.Mr. Lynard is a seasoned finance executive with over 20 years of global leadership experience in the life sciences industry  recognized for driving financial and operational transformation across complex  multinational organizations. His appointment follows our strong first half 2025 financial results and marks an important step in strengthening our financial leadership as we continue to execute on our growth strategy.Fabrice Chouraqui  Chief Executive Officer  commented:“We are delighted to welcome Kenneth to Pharming at a pivotal stage in our growth. Kenneth brings broad finance leadership capabilities from both established industry leaders and dynamic growth-stage companies  and operational experience in both the U.S. and EU. His strong value creation mindset  shaped by experience with companies backed by leading private equity firms  will be extremely valuable as we continue to advance our vision of building a leading global rare disease company.”Most recently  Mr. Lynard served as CFO of Schoeller Allibert and Zentiva  a European pharmaceutical company. He previously served as CFO at Affidea  and notably worked for Gilead Sciences  a leading US-based biopharmaceutical company  as Senior Vice President and CFO  Global Commercial Operations  R&D and Manufacturing  guiding the company through a successful transformation as it expanded into broader therapeutic areas and new geographies. During his five-year tenure at Gilead Sciences  he worked closely with top leadership on capital allocation and pipeline funding strategies  contributing to a tripling of the business following the Pharmasset acquisition. Earlier in his career  Mr. Lynard held finance leadership positions at Medtronic  Coloplast and Superfos. A former Big Five public accountant with Arthur Andersen  Mr. Lynard brings a solid foundation in compliance and internal controls  with a forward-looking approach to leveraging systems and data for business optimization.Kenneth Lynard commented:“I’m excited to join Pharming at such a pivotal moment in its evolution. The company’s strong growth momentum  combined with upcoming commercial and pipeline catalysts  reflects a solid foundation for long-term success. As the new Chief Financial Officer  I look forward to strengthening the foundations to enable continued operational efficiency and support sustainable value creation. What truly inspires me  however  is Pharming’s deep commitment to patients  especially those with few or no treatment options  and often unaware they are living with a rare disease. That purpose-driven mission is what makes this opportunity so meaningful.”Kenneth Lynard is a Danish citizen. He holds a Master of Science in Business Economics and Auditing from Copenhagen Business School  Denmark  and an executive MBA from the International Institute for Management Development (IMD) in Lausanne  Switzerland.About Pharming Group N.V.Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare  debilitating  and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines  including small molecules and biologics. Pharming is headquartered in Leiden  the Netherlands  and has employees around the globe who serve patients in over 30 markets in North America  Europe  the Middle East  Africa  and Asia-Pacific.For more information  visit www.pharming.com and find us on LinkedIn .Forward-Looking StatementsThis press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance  or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”  “ambition”  ‘‘anticipate’’  ‘‘believe’’  ‘‘could’’  ‘‘estimate’’  ‘‘expect’’  ‘‘goals’’  ‘‘intend’’  ‘‘may’’  “milestones”  ‘‘objectives’’  ‘‘outlook’’  ‘‘plan’’  ‘‘probably’’  ‘‘project’’  ‘‘risks’’  “schedule”  ‘‘seek’’  ‘‘should’’  ‘‘target’’  ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates  Pharming's clinical and commercial prospects  and Pharming's expectations regarding its projected working capital requirements and cash resources  which statements are subject to a number of risks  uncertainties and assumptions  including  but not limited to the scope  progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical  scientific  regulatory  commercial  competitive and technical developments. In light of these risks and uncertainties  and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31  2024  filed with the U.S. Securities and Exchange Commission  the events and circumstances discussed in such forward-looking statements may not occur  and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information.For further public information  contact:Pharming Group  Leiden  the NetherlandsMichael Levitan  VP Investor Relations & Corporate CommunicationsT: +1 (908) 705 1696Saskia Mehring  Corporate Communications ManagerT: +31 6 28 32 60 41E: investor@pharming.comFTI Consulting  London  UKSimon Conway/Alex ShawithAmy ByrneT: +44 203 727 1000LifeSpring Life Sciences Communication  Amsterdam  the NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nlUS PREthan MetelenisT: +1 (917) 882-9038E: Ethan.Metelenis@precisionaq.comAttachment,neutral,0.01,0.99,0.0,mixed,0.58,0.17,0.25,True,English,"['Chief Financial Officer', 'Pharming Group', 'Kenneth Lynard', 'former Big Five public accountant', 'strong first half 2025 financial results', 'leading global rare disease company', 'leading private equity firms', 'strong value creation mindset', 'leading US-based biopharmaceutical company', 'clinical, scientific, regulatory, c', 'broad finance leadership capabilities', 'Pharming Group N.V.', 'new Chief Financial Officer', 'sustainable value creation', 'global biopharmaceutical company', 'Chief Executive Officer', 'finance leadership positions', 'seasoned finance executive', 'complex, multinational organizations', 'Senior Vice President', 'broader therapeutic areas', 'strong growth momentum', 'European pharmaceutical company', 'Global Commercial Operations', 'pipeline funding strategies', 'working capital requirements', 'continued operational efficiency', 'global leadership experience', 'Copenhagen Business School', 'life sciences industry', 'financial leadership', 'actual results', 'new geographies', 'top leadership', 'executive MBA', 'industry leaders', 'capital allocation', 'pipeline catalysts', 'operational transformation', 'operational experience', 'Gilead Sciences', 'clinical trials', 'Mr. Lynard', 'important step', 'growth strategy', 'Fabrice Chouraqui', 'pivotal stage', 'U.S.', 'Schoeller Allibert', 'R&D', 'successful transformation', 'five-year tenure', 'Pharmasset acquisition', 'Arthur Andersen', 'solid foundation', 'internal controls', 'looking approach', 'business optimization', 'pivotal moment', 'upcoming commercial', 'long-term success', 'deep commitment', 'treatment options', 'purpose-driven mission', 'Danish citizen', 'Business Economics', 'International Institute', 'life-threatening diseases', 'innovative medicines', 'small molecules', 'North America', 'Middle East', 'press release', 'preclinical studies', 'product candidates', 'cash resources', 'future expectations', 'current expectations', 'Kenneth Lynard', 'Forward-Looking Statements', 'Management Development', 'EURONEXT Amsterdam', 'similar terms', 'unknown risks', 'Leiden', 'Netherlands', 'Nasdaq', 'appointment', 'CFO', '20 years', 'EU.', 'companies', 'vision', 'Zentiva', 'Affidea', 'Manufacturing', 'tripling', 'career', 'Medtronic', 'Coloplast', 'Superfos', 'compliance', 'systems', 'data', 'evolution', 'foundations', 'patients', 'opportunity', 'Master', 'Auditing', 'Denmark', 'IMD', 'Lausanne', 'Switzerland', 'lives', 'portfolio', 'biologics', 'employees', 'globe', '30 markets', 'Africa', 'Asia-Pacific', 'information', 'LinkedIn', 'assumptions', 'uncertainties', 'performance', 'events', 'use', 'phrases', 'aim', 'ambition', 'goals', 'milestones', 'objectives', 'outlook', 'plan', 'project', 'target', 'Examples', 'respect', 'timing', 'progress', 'prospects', 'number', 'scope', 'expansion', 'ramifications', 'cost']",2025-09-02,2025-09-03,globenewswire.com
52646,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2025/09/02/3142418/0/en/Virtune-AB-Publ-Virtune-has-completed-the-first-rebalancing-for-August-2025-of-its-Virtune-Coinbase-50-Index-ETP.html,"Virtune AB (Publ) (""Virtune"") has completed the first rebalancing for August 2025 of its Virtune Coinbase 50 Index ETP",Stockholm  September 2nd  2025 – Virtune today announces the completion of the first rebalancing for the Virtune Coinbase 50 Index ETP (ISIN: SE0024738389)  listed on Nasdaq Stockholm and Helsinki  Euronext Amsterdam and Paris and Deutsche Börse Xetra.,Stockholm  September 2nd  2025 – Virtune today announces the completion of the first rebalancing for the Virtune Coinbase 50 Index ETP (ISIN: SE0024738389)  listed on Nasdaq Stockholm and Helsinki  Euronext Amsterdam and Paris and Deutsche Börse Xetra.In addition to the Virtune Coinbase 50 Index ETP  Virtune’s product portfolio includes:Virtune Bitcoin ETPVirtune Staked Ethereum ETPVirtune XRP ETPVirtune Staked Solana ETPVirtune Staked Polkadot ETPVirtune Crypto Altcoin Index ETPVirtune Crypto Top 10 Index ETPVirtune Litecoin ETPVirtune Avalanche ETPVirtune Chainlink ETPVirtune Arbitrum ETPVirtune Staked Polygon ETPVirtune Staked Cardano ETPVirtune Bitcoin Prime ETPVirtune Stellar ETPVirtune Staked NEAR ETPIndex allocation as of August 28th (before rebalancing):Bitcoin: 40.66%Ethereum: 33.84%XRP: 10.86%Solana: 6.88%Cardano: 1.89%Chainlink: 1.03%Avalanche: 0.64%Stellar: 0.74%Bitcoin Cash: 0.68%Litecoin: 0.53%Polkadot: 0.39%Aave: 0.29%Uniswap: 0.39%Near: 0.19%Aptos: 0.17%Ethereum Classic: 0.20%Internet Computer: 0.17%Polygon: 0.14%Algorand: 0.13%Cosmos: 0.11%Curve DAO Token: 0.07%Index allocation as of August 29th (after rebalancing):Bitcoin: 50.00%Ethereum: 28.86%XRP: 9.06%Solana: 5.50%Cardano: 1.60%Chainlink: 0.86%Stellar: 0.64%Bitcoin Cash: 0.58%Avalanche: 0.53%Litecoin: 0.44%Uniswap: 0.33%Polkadot: 0.32%Aave: 0.26%Ethereum Classic: 0.17%Near: 0.16%Aptos: 0.16%Internet Computer: 0.14%Algorand: 0.12%Polygon: 0.11%Cosmos: 0.11%Curve DAO Token: 0.06%The index is rebalanced quarterly to reflect market changes and ensure it continues to represent the most relevant and qualitative crypto assets. The rebalancing adjusts the weighting based on market capitalization and may involve removing or adding certain assets.This rebalancing introduces no changes to the crypto assets included in the index. The performance of Virtune Coinbase 50 Index ETP in August was +3.05%Virtune Coinbase 50 Index ETP is a physically-backed exchange-traded product (ETP) tracking the Coinbase 50 Europe Index  the premier global benchmark index for digital assets and the crypto market’s equivalent of the S&P 500 index. The ETP provides exposure to up to 50 leading crypto assets and is rebalanced quarterly. The product features a transparent structure backed by physical holdings and secured with institutional-level solutions.If you  as an (institutional) investor  are interested in meeting with Virtune to discuss the opportunities our ETPs offer for your asset management services or to learn more about Virtune and our ETPs  please do not hesitate to contact us at hello@virtune.com. You can also read more about Virtune and our ETPs at www.virtune.com and register your email address on our website to subscribe to our newsletters  which cover updates on Virtune's upcoming ETP launches and other news related to digital assets.Press contactChristopher Kock  CEO Virtune AB (Publ)Christopher@virtune.com+46 70 073 45 64Virtune  headquartered in Stockholm  is a regulated Swedish digital asset manager and issuer of crypto exchange traded products on regulated European exchanges. With regulatory compliance  strategic collaborations with industry leaders and our proficient team  we empower investors on a global level to access innovative and sophisticated investment products that are aligned with the evolving landscape of the global crypto market.Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value  and there is no guarantee that you will recover your invested capital. Please read the prospectus  KID  terms at www.virtune.com.. The Coinbase 50 Europe Index (“Index”) is the exclusive property of MarketVector Indexes GmbH (“MarketVector”) and its Licensors and has been licensed for use by Virtune AB (Publ) (“Licensee”). MarketVector has contracted with CC Data Limited to maintain and calculate the Index. CC Data Limited uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector  CC Data Limited has no obligation to point out errors in the Index to third parties. In particular  MarketVector is not responsible for the Licensee and/or for Licensee’s legality or suitability and/or for Licensee’s business offerings. Offerings by Licensee  may they be based on the Virtune Coinbase 50 Europe ETP (“Product”) or not  are not sponsored  endorsed  sold  or promoted by MarketVector and any of its affiliates  and MarketVector and any of its affiliates make no representation regarding the advisability of investing in Licensee and/or in Licensee’s business offerings. MARKETVECTOR AND ANY OF ITS AFFILIATES AND ANY OF ITS LICENSORS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO LICENSEE.,neutral,0.01,0.99,0.0,negative,0.0,0.22,0.78,True,English,"['Virtune Coinbase 50 Index ETP', 'Virtune AB', 'first rebalancing', 'Publ', 'August', 'Virtune Staked Cardano ETP Virtune Bitcoin Prime ETP Virtune Stellar ETP Virtune Staked', 'Virtune XRP ETP Virtune Staked Solana ETP Virtune Staked Polkadot ETP', 'Virtune Litecoin ETP Virtune Avalanche ETP', 'Virtune Staked Polygon ETP', 'Virtune Crypto Altcoin Index ETP', 'Virtune Crypto Top 10 Index ETP', 'Virtune Bitcoin ETP Virtune', 'Virtune Coinbase 50 Europe ETP', 'Virtune Coinbase 50 Index ETP', 'Deutsche Börse Xetra', 'NEAR ETP Index allocation', 'Swedish digital asset manager', 'premier global benchmark index', 'Virtune Arbitrum ETP', 'The Coinbase 50 Europe Index', 'Virtune Chainlink ETP', 'upcoming ETP launches', 'CEO Virtune AB', 'asset management services', 'Curve DAO Token', 'CC Data Limited', 'S&P 500 index', 'The ETP', 'global crypto market', 'qualitative crypto assets', '50 leading crypto assets', 'regulated European exchanges', 'backed exchange-traded product', 'sophisticated investment products', 'Ethereum ETP', 'MarketVector Indexes GmbH', 'Bitcoin Cash', 'crypto exchange', 'global level', 'digital assets', 'investment advice', 'market capitalization', 'Euronext Amsterdam', 'Internet Computer', 'up to', 'transparent structure', 'physical holdings', 'institutional-level solutions', 'institutional) investor', 'email address', 'other news', 'Press contact', 'regulatory compliance', 'strategic collaborations', 'industry leaders', 'proficient team', 'evolving landscape', 'exclusive property', 'best efforts', 'third parties', 'product portfolio', 'market changes', 'August 28th', 'August 29th', 'business offerings', 'Ethereum Classic', 'Christopher Kock', 'Cryptocurrency investments', 'high risk', 'first rebalancing', 'Nasdaq Stockholm', 'completion', 'ISIN', 'Helsinki', 'Paris', 'addition', 'Aave', 'Uniswap', 'Aptos', 'Algorand', 'Cosmos', 'relevant', 'weighting', 'performance', 'equivalent', 'exposure', 'opportunities', 'ETPs', 'hello', 'website', 'newsletters', 'updates', 'Publ', 'issuer', 'investors', 'innovative', 'Securities', 'value', 'guarantee', 'prospectus', 'KID', 'terms', 'Licensors', 'use', 'Licensee', 'obligations', 'errors', 'legality', 'suitability', 'affiliates', 'representation', 'advisability', 'WARRANTIES', 'LIABILITY', 'RESPECT', '0.', '1.60']",2025-09-02,2025-09-03,globenewswire.com
52647,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2025/09/02/3142982/0/en/TOUAX-Disclosure-of-Share-Capital-and-Voting-Rights.html,TOUAX : Disclosure of Share Capital and Voting Rights,REGULATED INFORMATION                Paris  2 September 2025 5:45 PM  YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION  Disclosure of...,REGULATED INFORMATION Paris  2 September 2025 5:45 PMYOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATIONDisclosure of Share Capital and Voting RightsDisclosure of Share Capital and Voting Rights pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.Register name of the issuer: TOUAX SCA (Euronext Growth Paris: ALTOU)Date Total shares outstanding Total voting rights Total exercisable voting rights* August 31  2025 7 011 547 8 364 330 8 326 131* excluding rights attached to shares held in treasury****************TOUAX Group leases out tangible assets (freight railcars  river barges and containers) on a daily basis throughout the world  for its own account and on behalf of third party investors. With €1.3 billion under management  TOUAX is one of the European leaders in the operational leasing of this type of equipment.TOUAX SCA is listed on Euronext Growth Paris (ISIN code FR0000033003  ticker ALTOU) and on the CAC® Small  CAC® Mid & Small  CAC® All Shares  CAC® All-Tradable  Euronext Growth All-Share and EnterNext©PEA-PME 150.For more information: www.touax.comContacts:TOUAX SEITOSEI ● ACTIFINFabrice & Raphaël WALEWSKI Ghislaine GASPARETTOManaging Partners ghislaine.gasparetto@seitosei-actifin.comtouax@touax.comwww.touax.com Tel: +33 (0)1 56 88 11 11Tel: +33 (0)1 46 96 18 00Attachment,neutral,0.0,1.0,0.0,neutral,0.03,0.96,0.01,True,English,"['Share Capital', 'Voting Rights', 'TOUAX', 'Disclosure', 'Autorité des Marchés Financiers', 'Total exercisable voting rights', 'third party investors', 'Date Total shares', 'French Commercial Code', 'Raphaël WALEWSKI', 'Managing Partners ghislaine', 'Total voting rights', 'OPERATIONAL LEASING SOLUTION', 'Euronext Growth Paris', 'CAC® All Shares', 'ISIN code', 'SUSTAINABLE TRANSPORTATION', 'Share Capital', 'Article L.', 'General Regulations', 'Register name', 'tangible assets', 'freight railcars', 'river barges', 'daily basis', 'European leaders', 'EnterNext©PEA-PME', 'ACTIFIN Fabrice', 'Ghislaine GASPARETTO', 'CAC® Small', 'REGULATED INFORMATION', 'TOUAX SCA', 'TOUAX Group', 'TOUAX SEITOSEI', '2 September', 'Disclosure', 'issuer', 'ALTOU', 'treasury', 'containers', 'world', 'account', 'behalf', 'management', 'type', 'equipment', 'ticker', 'Contacts', 'Tel', 'Attachment', '45', '33', '1 56']",2025-09-02,2025-09-03,globenewswire.com
52648,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2025/09/02/3143157/0/en/Nanobiotix-to-Participate-in-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html,Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference,PARIS and CAMBRIDGE  Mass.  Sept. 02  2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’)  a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients w…,PARIS and CAMBRIDGE  Mass.  Sept. 02  2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’)  a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases  announced today that Company management will participate in a fireside chat at following conference:H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday  September 9th  2025Time: 9:00 am EDT / 3:00 pm CESTLocation: New York  NYPresenters: Laurent Levy  Chief Executive Officer of Nanobiotix & Bart van Rhijn  Chief Financial & Business Officer of NanobiotixWebcast link: Click hereThe fireside chat will be webcast live from the events page of the Investors section of the Company’s website. The replay of the webcast will be available following the event.About NANOBIOTIXNanobiotix is a late-stage clinical biotechnology company pioneering disruptive  physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.Incorporated in 2003  Nanobiotix is headquartered in Paris  France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge  Massachusetts (United States) amongst other locations.Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.For more information about Nanobiotix  visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.ContactsNanobiotix Communications DepartmentBrandon OwensVP  Communications+1 (617) 852-4835contact@nanobiotix.com Investor Relations DepartmentJoanne ChoiVP  Investor Relations (US)+1 (713) 609-3150Ricky BhajunDirector  Investor Relations (EU)+33 (0) 79 97 29 99investors@nanobiotix.com Media RelationsFrance – HARDYCaroline Hardy+33 06 70 33 49 50carolinehardy@outlook.fr Global – LifeSci AdvisorsKevin Gardner+1 (617) 283-2856kgardner@lifesciadvisors.comAttachment,neutral,0.02,0.98,0.0,negative,0.0,0.01,0.99,True,English,"['H.C. Wainwright 27th Annual Global Investment Conference', 'Nanobiotix', '27th Annual Global Investment Conference Date', 'Nasdaq Global Select Market', 'disruptive, physics-based therapeutic approaches', 'late-clinical stage biotechnology company', 'late-stage clinical biotechnology company', 'H.C. Wainwright', 'Bart van Rhijn', 'three (3) nanotechnology platforms', 'central nervous system', 'Ricky Bhajun Director', 'other major diseases', 'Chief Executive Officer', 'New York City', 'Investor Relations Department', 'Nanobiotix Communications Department', 'nanoparticle-based approaches', 'Chief Financial', 'Business Officer', 'other locations', 'Company management', 'The Company', 'Media Relations', 'GLOBE NEWSWIRE', 'fireside chat', 'Laurent Levy', 'events page', 'Investors section', 'treatment outcomes', 'human life', 'United States', '25 patent families', 'Brandon Owens', 'Joanne Choi', 'LifeSci Advisors', 'Kevin Gardner', 'treatment possibilities', 'Webcast link', 'Caroline Hardy', 'Euronext Paris', 'CAMBRIDGE', 'Mass.', 'NBTX', 'patients', 'cancer', 'Tuesday', '9th', 'Time', 'Presenters', 'website', 'replay', 'millions', 'people', 'difference', 'humanity', 'philosophy', 'concept', 'boundaries', 'France', 'December', 'subsidiaries', 'Massachusetts', 'owner', 'applications', 'oncology', 'bioavailability', 'biodistribution', 'disorders', 'information', 'LinkedIn', 'Twitter', 'Contacts', 'VP', 'carolinehardy', 'kgardner', 'lifesciadvisors', 'Attachment', '9:00', '3:00', '06']",2025-09-02,2025-09-03,globenewswire.com
52649,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/paratus-ex-dividend-usd-0-22-per-share-today-302543501.html,Paratus: Ex-Dividend USD 0.22 per share today,"Hamilton  Bermuda  Sept. 2  2025 /PRNewswire/ -- Reference is made to the announcement by Paratus Energy Services Ltd. (OSE: PLSV) (""Paratus"" or the ""Company"") on August 26  2025  regarding key information relating to the Q2 2025 cash distribution to be paid …","Hamilton  Bermuda  Sept. 2  2025 /PRNewswire/ -- Reference is made to the announcement by Paratus Energy Services Ltd. (OSE: PLSV) (""Paratus"" or the ""Company"") on August 26  2025  regarding key information relating to the Q2 2025 cash distribution to be paid to the Company's shareholders. The shares in Paratus will be traded ex dividend of USD 0.22 (approximately NOK 2.23) per share as from today  2 September 2025.The payment date will be on or about 16 September 2025.This information is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act.For further information  please contact:Baton Haxhimehmedi  CFOBaton.Haxhimehmedi@paratus-energy.com+47 406 39 083About ParatusParatus Energy Services Ltd. (OSE: PLSV) is an investment holding company of a group of leading energy services companies. The Paratus Group is primarily comprised of its ownership of Fontis Energy and a 50/50 JV interest in Seagems. Fontis Energy is an offshore drilling company with a fleet of five high-specification jack-up rigs in Mexico. Seagems is a leading subsea services company  with a fleet of six multi-purpose pipe-laying support vessels in Brazil. In addition  Paratus is the largest shareholder in Archer Ltd  a global oil services company  listed on the Euronext Oslo Børs.This information was brought to you by Cision http://news.cision.comhttps://news.cision.com/paratus-energy-services-ltd/r/paratus--ex-dividend-usd-0-22-per-share-today c4222887",neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['Paratus', 'Ex-Dividend', 'share', 'six multi-purpose pipe-laying support vessels', 'Norwegian Securities Trading Act', 'five high-specification jack-up rigs', 'Euronext Oslo Børs', 'leading energy services companies', 'leading subsea services company', 'global oil services company', 'Paratus Energy Services Ltd', 'Q2 2025 cash distribution', '50/50 JV interest', 'investment holding company', 'offshore drilling company', 'The Paratus Group', 'Archer Ltd', 'Fontis Energy', 'payment date', 'disclosure requirements', 'CFO Baton', 'largest shareholder', 'Baton Haxhimehmedi', 'key information', 'news.cision', 'Hamilton', 'Bermuda', 'PRNewswire', 'Reference', 'announcement', 'PLSV', 'August', 'shareholders', 'shares', 'dividend', 'USD', 'NOK', 'today', '2 September', '16 September', 'section', 'ownership', 'Seagems', 'fleet', 'Mexico', 'Brazil', 'addition', 'paratus-energy-services']",2025-09-02,2025-09-03,prnewswire.co.uk
52650,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2025/09/02/3142987/0/en/Bureau-Veritas-Ranks-Top-Performer-in-S-P-Global-CSA-Score-2025.html,Bureau Veritas Ranks Top Performer in S&P Global CSA Score 2025,PRESS RELEASE    Courbevoie  France – September 2  2025     Bureau Veritas Ranks Top Performer in S&P Global CSA Score 2025      Bureau Veritas is......,PRESS RELEASECourbevoie  France – September 2  2025Bureau Veritas Ranks Top Performer in S&P Global CSA Score 2025Bureau Veritas is honored and proud to announce that it has improved its ESG performance in the S&P Global Corporate Sustainability Assessment (CSA). Revealed in August 2025  the company's score reaches 84 out of 100 points  positioning it in first place among Professional Services sector companies – which encompasses the TIC sector.This achievement highlights the significant progress made by Bureau Veritas across various ESG dimensions:Environment: Continued development of Environmental Management PolicySocial: Ongoing strengthening of Customer SatisfactionGovernance: Improvement of Transparency  Reporting  and Risk Management practices.This distinction marks the seventh consecutive year Bureau Veritas has distinguished itself in the Dow Jones Sustainability Indices (DJSI). It reflects the constant commitment of the company's 84 000 employees to embody a reference model in sustainability.ABOUT BUREAU VERITASBureau Veritas is a world leader in inspection  certification  and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability  the company innovates to help them navigate change.Created in 1828  Bureau Veritas’ 84 000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality  health and safety  environmental protection  and sustainability.Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 and CAC 40 ESG indices and is part of the CAC SBT 1.5° index. Compartment A  ISIN code FR 0006174348  stock symbol: BVI.For more information  visit www.bureauveritas.com   and follow us on LinkedIn and X/Twitter .ABOUT THE S&P GLOBAL CSAThe S&P Global Corporate Sustainability Assessment (CSA) is a benchmark annual evaluation of corporate sustainability practices. Covering over 12 000 companies across 62 industrial sectors  the CSA uses a rigorous multi-criteria analysis methodology  evaluating each organization through 110 questions across environmental  social  and governance dimensions. Its unique double materiality methodology allows measuring not only companies' impact on society and the environment but also how sustainability issues influence their performance and value creation. The ESG score  rated out of 100  offers investors and stakeholders a comparative and in-depth vision of companies' sustainable development strategies on a global scale.Our information is certified with blockchain technology.Check that this press release is genuine at www.wiztrust.com .ANALYST/INVESTOR CONTACTSMEDIA CONTACTSLaurent BrunelleMartin Bovo+33 (0)1 55 24 76 09+33 (0)6 14 46 79 94laurent.brunelle@bureauveritas.commartin.bovo@bureauveritas.comColin Verbrugghe+33 (0)1 55 24 77 80colin.verbrugghe@bureauveritas.comRomain Gorge+33 (0)6 31 68 29 92romain.gorge@bureauveritas.comAttachment,neutral,0.16,0.84,0.0,positive,0.84,0.16,0.0,True,English,"['S&P Global CSA Score', 'Bureau Veritas', 'Top Performer', 'The S&P Global Corporate Sustainability Assessment', 'S&P Global CSA Score', 'rigorous multi-criteria analysis methodology', 'unique double materiality methodology', 'Dow Jones Sustainability Indices', 'Environmental Management Policy Social', ""companies' sustainable development strategies"", 'Professional Services sector companies', 'corporate sustainability practices', 'Risk Management practices', 'The ESG score', 'seventh consecutive year', 'benchmark annual evaluation', 'laboratory testing services', 'CAC 40 ESG indices', 'Customer Satisfaction Governance', 'CAC SBT 1.5° index', 'various ESG dimensions', 'global scale', 'sustainability issues', 'TIC sector', 'Continued development', 'environmental protection', 'governance dimensions', ""companies' impact"", 'ESG performance', 'PRESS RELEASE', 'Bureau Veritas', 'Top Performer', 'first place', 'significant progress', 'Ongoing strengthening', 'constant commitment', 'reference model', 'powerful purpose', 'responsible progress', 'preferred partner', 'technical experts', 'Euronext Paris', 'Compartment A', 'ISIN code', 'stock symbol', '62 industrial sectors', 'value creation', 'blockchain technology', 'ANALYST/INVESTOR CONTACTS', 'MEDIA CONTACTS', 'world leader', 'customers’ excellence', 'depth vision', 'Laurent Brunelle', 'Martin Bovo', 'Colin Verbrugghe', 'Romain Gorge', '12,000 companies', 'Courbevoie', 'France', 'September', 'August', 'company', '100 points', 'achievement', 'Improvement', 'Transparency', 'Reporting', 'distinction', 'DJSI', '84,000 employees', 'inspection', 'certification', 'trust', 'change', '140 countries', 'challenges', 'health', 'safety', 'BVI.', 'information', 'bureauveritas', 'LinkedIn', 'X/Twitter', 'organization', '110 questions', 'society', 'investors', 'stakeholders', 'comparative', 'Attachment', '1 55']",2025-09-02,2025-09-03,globenewswire.com
52651,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2025/09/02/3142313/0/en/Weekly-progress-on-share-repurchase-program-to-cover-share-plans-and-reduce-capital.html,Weekly progress on share repurchase program to cover share plans and reduce capital,Press Release  Weekly progress on share repurchase program to cover share plans and reduce capital  Kaiseraugst (Switzerland)  Maastricht...,Press ReleaseWeekly progress on share repurchase program to cover share plans and reduce capitalKaiseraugst (Switzerland)  Maastricht (Netherlands)  September 2  2025dsm-firmenich  innovators in nutrition  health  and beauty  announced on February 13  2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital  starting with an initial €500 million. On April 1  2025  the company commenced a program to repurchase ordinary shares for a total amount of €580 million  of which €80 million to cover commitments under the Group’s share-based compensation plans and €500 million to reduce its issued capital.On June 27  2025  the company announced the increase of the share repurchase program to €1 080 million following the completion of the previously announced sale of dsm-firmenich’s stake in the Feed Enzymes Alliance.In accordance with regulations  dsm-firmenich informs the market that during the period from August 25  2025 up to and including August 29  2025 a total number of 268 061 shares have been repurchased on its behalf. The shares were repurchased at an average price of €83.95 per share for a total amount of €22.5 million.The total number of shares repurchased under this program to date is 7 267 546 shares at an average price of €90.50 for a total consideration of €657.7 million.This €1 080 million share repurchase program will be completed no later than January 30  2026.For more detailed information see ‘Daily transaction details Share Repurchase Program announced April 1  2025’.For more information  please contact:dsm-firmenich investor relations enquiries:Email: investors@dsm-firmenich.comdsm-firmenich media enquiries:Email: media@dsm-firmenich.comAbout dsm-firmenichAs innovators in nutrition  health  and beauty  dsm-firmenich reinvents  manufactures  and combines vital nutrients  flavors  and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions  with natural and renewable ingredients and renowned science and technology capabilities  we work to create what is essential for life  desirable for consumers  and more sustainable for the planet. dsm-firmenich is a Swiss company with dual headquarters in Kaiseraugst  Switzerland and Maastricht  Netherlands  listed on the Euronext Amsterdam  with operations in almost 60 countries and revenues of more than €12 billion. With a diverse  worldwide team of nearly 30 000 employees  we bring progress to life every day  everywhere  for billions of people. www.dsm-firmenich.comDisclaimerThis press release does not constitute or form part of  an offer or any solicitation of an offer for securities in any jurisdiction. This press release may contain forward-looking statements with respect to dsm-firmenich’s future. Such statements are based on current expectations  estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release  unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.Attachment,neutral,0.09,0.91,0.0,negative,0.0,0.0,1.0,True,English,"['share repurchase program', 'share plans', 'Weekly progress', 'capital', 'EU Market Abuse Regulation', 'dsm-firmenich investor relations enquiries', '€1,080 million share repurchase program', 'Feed Enzymes Alliance', 'Daily transaction details', 'diverse, worldwide team', 'English language version', 'other language versions', 'aggregate market value', 'share-based compensation plans', 'dsm-firmenich media enquiries', 'share plans', 'Press Release', 'total amount', 'total number', 'average price', 'total consideration', 'vital nutrients', 'growing population', 'comprehensive range', 'renewable ingredients', 'renowned science', 'technology capabilities', 'dual headquarters', 'Euronext Amsterdam', 'current expectations', 'many factors', 'actual performance', 'Weekly progress', 'detailed information', 'looking statements', 'Such statements', 'inside information', 'ordinary shares', 'Swiss company', '268,061 shares', '7,267,546 shares', 'capital', 'Kaiseraugst', 'Switzerland', 'Maastricht', 'Netherlands', 'innovators', 'nutrition', 'health', 'beauty', 'February', 'intention', 'initial', 'April', 'commitments', 'Group', 'June', 'increase', 'completion', 'sale', 'stake', 'accordance', 'regulations', 'period', 'August', 'behalf', 'date', 'January', 'Email', 'investors', 'flavors', 'fragrances', 'solutions', 'natural', 'life', 'consumers', 'planet', 'operations', '60 countries', 'revenues', '30,000 employees', 'billions', 'people', 'Disclaimer', 'part', 'offer', 'solicitation', 'securities', 'jurisdiction', 'forward', 'respect', 'future', 'estimates', 'projections', 'readers', 'risks', 'uncertainties', 'position', 'obligation', 'law', 'communication', 'meaning', 'Article', 'Attachment']",2025-09-02,2025-09-03,globenewswire.com
52652,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2025/09/02/3143020/0/en/THEON-INTERNATIONAL-publishes-its-H1-2025-Report.html,THEON INTERNATIONAL publishes its H1 2025 Report,PRESS RELEASE  Bloomberg (THEON:NA) / Reuters (THEON.AS)    02 September 2025 - Theon International Plc (THEON) (AMS: THEON) is pleased to announce the......,"PRESS RELEASEBloomberg (THEON:NA) / Reuters (THEON.AS)02 September 2025 - Theon International Plc (THEON) (AMS: THEON) is pleased to announce the publication of its H1 2025 Report for the six months ended 30 June 2025. This follows the H1 2025 Trading Update published on 28 July 2025.The Company is holding a webcast for analysts and investors on September 4  2025 at 3:00 PM EEST (1:00 PM BST). The webcast details are accessible here.H1 2025 OverviewH1 2025 performance was characterised by robust order intake  achievement of financial targets and solid progress in THEON’s growth strategy.Revenue reached €183.7 million  marking the strongest H1 in THEON’S 28-year history.Continued strong order intake  with new orders reaching €167.9 million  118% higher than in H1 2024  and coming from multiple countries worldwide.Soft backlog of €622.2 million at end of H1 2025  45% higher than in H1 2024  with an additional €378.2 million of contractual options.Adjusted EBIT margin of 25.8% demonstrating industry leading margins and in line with the mid-twenties guidance.Several contract wins for market-leading night vision products as well as new digital products  and in advanced stages of several tender processes for a mix of products.Transitioning to an enriched broader product portfolio through recently developed A.R.M.E.D. ecosystem of products and near-term expansion into platform-based optronics products.Launch of “THEON Next” Vision & Strategy  encapsulating THEON’s ambition of becoming a trusted market leader in the next generation of optronics and a global player in the modern warfare era.Rapidly building a platform to drive the development of next-generation soldier systems through acquisitions and targeted investments  collaborations  and co-development initiatives.Christian Hadjiminas  founder and CEO of THEON commented on the H1 2025 results: ""Our record-breaking first-half revenue is a testament to the strength of our business model and the trust our customers place in us. The recent acquisition of Kappa Optronics  the signing of several pioneering agreements  and the launch of our THEON NEXT Strategy all mark key strategic milestones in our journey  accelerating our capabilities and growth trajectory.""Financial Summary(Amounts in €) H1 2025 H1 2024 Change Order intake 167.9 m 77.0 m +118.1% Revenue 183.7 m 152.4 m +20.6% Adjusted EBIT1 47.4 m (45.9 m) 38.1 m (36.9 m) +24.4% Adjusted EBIT margin1 25.8% (25.0%) 25.0% (24.2%) +0.8 p.p. Earnings per share 0.48 0.41 +17.1% Capex 6.7 m 5.1 m +31.4% (Amounts in €) Jun 2025 Mar 2025 Change Soft backlog 622.2 m 668.6 m -6.9% Net working capital 165.4 m 160.0 m +3.4% Net cash2 38.1 m 61.2 m -37.7%1 Reflects a change in accounting policy to include the Group’s share of profits from core equity-accounted investees within operating profit. Numbers in brackets are before the accounting policy change.2 Excluding the share buyback liability of €3.4m/6.7m in H1/Q1 2025.All numbers remain unchanged from those published at the time of the H1 2025 Trading Update on 28 July 2025The H1 2025 Report of THEON is now available for download on the company’s website.For inquiries  please contact:Investor RelationsNikos MalesiotisE-Mail: ir@theon.comTel: +30 210 6772290 Media ContactElli MichouE-Mail: press@theon.comTel: +30 210 6728610About THEON GROUPTHEON GROUP of companies develops and manufactures cutting-edge night vision and thermal Imaging systems for Defense and Security applications with a global footprint. THEON GROUP started its operations in 1997 from Greece and today occupies a leading role in the sector thanks to its international presence through subsidiaries and production facilities in Greece  Cyprus  Germany  the Baltics  the United States  the Gulf States  Switzerland  Denmark  Belgium  Singapore and South Korea. THEON GROUP has more than 220 000 systems in service with Armed and Special Forces in 71 countries around the world  26 of which are NATO countries. ΤΗΕΟΝ ΙΝΤΕRNATIONAL PLC has been listed on Euronext Amsterdam (AMS: THEON) since February 2024.www.theon.comAttachment",neutral,0.0,1.0,0.0,positive,0.89,0.11,0.0,True,English,"['THEON INTERNATIONAL', 'H1 2025 Report', 'A.R.M.E.D. ecosystem', 'market-leading night vision products', 'H1 2024 Change Order intake', 'cutting-edge night vision', 'robust order intake', 'strong order intake', 'broader product portfolio', 'trusted market leader', 'modern warfare era', 'key strategic milestones', 'core equity-accounted investees', 'several tender processes', 'several pioneering agreements', 'industry leading margins', 'Net working capital', 'next-generation soldier systems', 'thermal Imaging systems', 'H1 2025 Trading Update', 'new digital products', 'Change Soft backlog', 'accounting policy change', 'record-breaking first-half revenue', 'share buyback liability', 'THEON Next” Vision', 'platform-based optronics products', 'The H1 2025 Report', 'Theon International Plc', 'THEON NEXT Strategy', 'Several contract', 'next generation', 'new orders', 'Net cash2', 'leading role', 'international presence', 'ΙΝΤΕRNATIONAL PLC', 'H1 2025 Overview', 'H1 2025 performance', 'strongest H1', 'H1 2025 results', 'PRESS RELEASE', 'six months', 'The Company', 'financial targets', 'solid progress', 'growth strategy', '28-year history', 'contractual options', 'EBIT margin', 'mid-twenties guidance', 'advanced stages', 'near-term expansion', 'global player', 'Christian Hadjiminas', 'business model', 'recent acquisition', 'Kappa Optronics', 'growth trajectory', 'Financial Summary', 'operating profit', 'Investor Relations', 'Nikos Malesiotis', 'Media Contact', 'Elli Michou', 'Security applications', 'global footprint', 'production facilities', 'United States', 'Gulf States', 'South Korea', 'Special Forces', 'Euronext Amsterdam', 'multiple countries', 'NATO countries', 'THEON.AS', 'webcast details', 'development initiatives', 'THEON GROUP', '220,000 systems', '71 countries', 'Bloomberg', 'Reuters', '02 September', 'publication', '28 July', 'analysts', 'investors', '3:00 PM', 'achievement', 'line', 'mix', 'Launch', 'ambition', 'acquisitions', 'investments', 'collaborations', 'founder', 'CEO', 'testament', 'strength', 'customers', 'signing', 'journey', 'capabilities', 'Amounts', 'EBIT1', 'Earnings', 'Capex', 'Jun', 'profits', 'Numbers', 'brackets', 'H1/Q1', 'time', 'download', 'website', 'inquiries', 'Tel', 'companies', 'Defense', 'operations', 'Greece', 'sector', 'subsidiaries', 'Cyprus', 'Germany', 'Baltics', 'Switzerland', 'Denmark', 'Belgium', 'Singapore', 'service', 'Armed', 'world', 'February', 'Attachment', '30', '€', '36.9', 'ΤΗΕΟΝ']",2025-09-02,2025-09-03,globenewswire.com
52653,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2025/09/02/3143066/0/en/Medidata-Secures-a-Leader-Position-in-Everest-Group-s-PEAK-Matrix-Assessment-for-eCOA-Driving-the-New-Patient-Experience-Forward.html,Medidata Secures a Leader Position in Everest Group’s PEAK Matrix® Assessment for eCOA  Driving the New Patient Experience Forward,Medidata eCOA was the highest Leader recognized in the evaluation  supporting over 1M+ patients and reducing study build timeline by up to 50% compared to the industry standard Medidata eCOA was the highest Leader recognized in the evaluation  supporting over…,"NEW YORK  Sept. 02  2025 (GLOBE NEWSWIRE) -- Medidata  a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry  has been recognized as a Leader in Everest Group‘s Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment 2025. The report assessed 19 providers based on their demonstrated success in delivering products and driving impact within the life science industry  solidifying Medidata eCOA as a powerful solution for clinical trials and medical breakthroughs.""As the Leader in the eCOA market for over a decade  Medidata solutions  services  and support have been foundational to thousands of global studies across every indication ” said Nisarg Shah  research director  Everest. “Built on its reputation as the global Leader in clinical research technology  Medidata eCOA continues to revolutionize the market with innovations like Medidata Designer  which drastically reduces study design and startup timelines. Medidata’s commitment extends to delivering world-class expert advisory and scientific support services  helping with trial success  higher quality data  and superior experiences for patients and sites alike.""Driving the Medidata Patient Experience forward  Medidata eCOA combines cutting-edge technology and operational expertise to launch studies faster than the industry standard and maintain top data integrity  reducing study build time by up to six weeks compared to the industry standard of 12 or more weeks. With its recent partnership with Cogstate  Medidata eCOA was further enhanced with scientific rigor that aims to reduce rater burden and enhance signal detection in Central Nervous System (CNS) trials.“Achieving a Leader position in Everest Group's eCOA PEAK Matrix® Assessment underscores Medidata's relentless pursuit of innovation and our profound impact on enhancing the clinical trial experience for both sites and patients ” said Matt Noble  senior vice president  Patient Experience  Medidata.Medidata's consistent recognition by Everest Group in 2023 and 2024 for Decentralized Clinical Trials - a core element of the Patient Experience - underscores its leadership in the clinical trial space. Further accolades for Medidata Rave EDC and Medidata Rave CTMS  integral parts of the Medidata Data Experience and Medidata Study Experience  highlight the company's unwavering dedication to patients  sites  and sponsors  driving improved clinical trial operations and accelerating the delivery of life-saving therapies to market.To learn more about Medidata eCOA and the Everest Group report  visit here and here.About MedidataMedidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36 000 trials and 11 million patients  Medidata offers industry-leading expertise  analytics-powered insights  and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2 300 customers trust Medidata’s seamless  end-to-end platform to improve patient experiences  accelerate clinical breakthroughs  and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8  DSY.PA)  Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast  from Dreamers to Disruptors  and follow us at @Medidata.About Dassault SystèmesDassault Systèmes is a catalyst for human progress. Since 1981  the company has pioneered virtual worlds to improve real life for consumers  patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform  370 000 customers of all sizes  in all industries  can collaborate  imagine and create sustainable innovations that drive meaningful impact. For more information  visit: www.3ds.com.About Everest GroupEverest Group is a leading global research firm helping business leaders make confident decisions. Everest Group's PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers  locations  and products and solutions within various market segments. Likewise  providers of these services  products  and solutions  look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com.DisclaimerLicensed extracts taken from Everest Group’s PEAK Matrix® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology  please visit Everest Group PEAK Matrix® Reports.Contact:Medidata PRMedidata.PR@3ds.comAnalyst Relationsmedidata.AR@3ds.com",neutral,0.01,0.99,0.0,neutral,0.04,0.95,0.01,True,English,"['New Patient Experience Forward', 'PEAK Matrix® Assessment', 'Leader Position', 'Everest Group', 'Medidata', 'eCOA', 'Life Sciences Electronic Clinical Outcome Assessment', 'A Dassault Systèmes brand', 'Dassault Systèmes’ 3DEXPERIENCE platform', 'largest clinical trial data sets', 'eCOA PEAK Matrix® Assessment', 'leading global research firm', 'PEAK Matrix® Assessment 2025', 'life sciences industry', 'higher quality data', 'top data integrity', 'clinical trial space', 'clinical trial operations', 'clinical trial experience', 'world-class expert advisory', 'Central Nervous System', 'senior vice president', 'PEAK Matrix® assessments', 'PEAK Matrix® Reports', 'study build time', 'life science industry', '1 million registered users', 'critical selection decisions', 'Decentralized Clinical Trials', 'clinical trial solutions', 'ground-breaking technological innovation', 'New York City', 'Medidata Data Experience', 'clinical research technology', 'Medidata Rave EDC', 'Medidata Rave CTMS', 'various market segments', 'Medidata Study Experience', 'Medidata Patient Experience', 'scientific support services', 'global services providers', 'Everest Group report', 'end platform', 'real life', 'clinical breakthroughs', 'leading provider', 'study design', 'trial success', 'cutting-edge technology', 'scientific rigor', 'confident decisions', 'global studies', 'patient experiences', 'research director', 'global Leader', 'GLOBE NEWSWIRE', 'powerful solution', 'medical breakthroughs', 'Nisarg Shah', 'startup timelines', 'superior experiences', 'operational expertise', 'industry standard', 'recent partnership', 'rater burden', 'signal detection', 'CNS) trials', 'relentless pursuit', 'Matt Noble', 'consistent recognition', 'core element', 'Further accolades', 'integral parts', 'unwavering dedication', 'smarter treatments', 'healthier people', 'industry-leading expertise', 'Euronext Paris', 'latest podcast', 'human progress', 'virtual worlds', 'business leaders', 'depth content', 'third parties', 'promotional activities', 'full context', 'Medidata eCOA', 'digital solutions', 'eCOA market', 'Medidata Designer', '11 million patients', 'profound impact', 'meaningful impact', 'Medidata solutions', 'eCOA) Products', 'six weeks', 'life-saving therapies', 'analytics-powered insights', 'sustainable innovations', 'Licensed extracts', 'Leader position', '36,000 trials', '19 providers', 'demonstrated', 'decade', 'thousands', 'indication', 'reputation', 'commitment', 'sites', 'Cogstate', 'leadership', 'company', 'sponsors', 'delivery', '25 years', 'More', '2,300 customers', 'DSY', 'IDC', 'Dreamers', 'Disruptors', 'catalyst', 'consumers', 'citizens', '370,000 customers', 'sizes', 'industries', 'information', '3ds', 'analysis', 'enterprises', 'locations', 'offerings', 'others', 'details', 'everestgrp', 'Disclaimer', 'marketing', 'collateral', 'analysts', 'organization', 'fee', 'ranking', '12']",2025-09-02,2025-09-03,globenewswire.com
52654,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2025/09/02/3142320/0/en/Progress-on-share-buyback-programme.html,Progress on share buyback programme,Progress on share buyback programme  ING announced today that  as part of our €2.0 billion share buyback programme announced on 2 May 2025  in total......,Progress on share buyback programmeING announced today that  as part of our €2.0 billion share buyback programme announced on 2 May 2025  in total 2 442 722 shares were repurchased during the week of 25 August 2025 up to and including 29 August 2025.The shares were repurchased at an average price of €20.72 for a total amount of €50 622 708.86. For detailed information on the daily repurchased shares  individual share purchase transactions and weekly reports  see the ING website at www.ing.com/investorrelations.In line with the purpose of the programme to reduce the share capital of ING  the total number of shares repurchased under this programme to date is 67 646 910 at an average price of €19.03 for a total consideration of €1 287 254 023.33. To date approximately 64.36% of the maximum total value of the share buyback programme has been completed.Note for editorsFor further information on ING  please visit www.ing.com. Frequent news updates can be found in the Newsroom. Photos of ING operations  buildings and its executives are available for download at Flickr.Press enquiries Investor enquiries Raymond Vermeulen ING Group Investor Relations +31 20 576 5000 +31 20 576 6396 Raymond.Vermeulen@ing.com Investor.Relations@ing.comING PROFILEING is a global financial institution with a strong European base  offering banking services through its operating company ING Bank. The purpose of ING Bank is: empowering people to stay a step ahead in life and in business. ING Bank’s more than 60 000 employees offer retail and wholesale banking services to customers in over 100 countries.ING Group shares are listed on the exchanges of Amsterdam (INGA NA  INGA.AS)  Brussels and on the New York Stock Exchange (ADRs: ING US  ING.N).ING aims to put sustainability at the heart of what we do. Our policies and actions are assessed by independent research and ratings providers  which give updates on them annually. ING's ESG rating by MSCI was reconfirmed by MSCI as 'AA' in August 2024 for the fifth year. As of June 2025  in Sustainalytics’ view  ING’s management of ESG material risk is ‘Strong’ with an ESG risk rating of 18.0 (low risk). ING Group shares are also included in major sustainability and ESG index products of leading providers. Here are some examples: Euronext  STOXX  Morningstar and FTSE Russell. Society is transitioning to a low-carbon economy. So are our clients  and so is ING. We finance a lot of sustainable activities  but we still finance more that’s not. Follow our progress on ing.com/climate.IMPORTANT LEGAL INFORMATIONElements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/2014 (‘Market Abuse Regulation’).ING Group’s annual accounts are prepared in accordance with International Financial Reporting Standards as adopted by the European Union (‘IFRS- EU’). In preparing the financial information in this document  except as described otherwise  the same accounting principles are applied as in the 2024 ING Group consolidated annual accounts. All figures in this document are unaudited. Small differences are possible in the tables due to rounding.Certain of the statements contained herein are not historical facts  including  without limitation  certain statements made of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to diﬀer materially from those expressed or implied in such statements. Actual results  performance or events may diﬀer materially from those in such statements due to a number of factors  including  without limitation: (1) changes in general economic conditions and customer behaviour  in particular economic conditions in ING’s core markets  including changes affecting currency exchange rates and the regional and global economic impact of the invasion of Russia into Ukraine and related international response measures (2) changes affecting interest rate levels (3) any default of a major market participant and related market disruption (4) changes in performance of financial markets  including in Europe and developing markets (5) fiscal uncertainty in Europe and the United States (6) discontinuation of or changes in ‘benchmark’ indices (7) inflation and deflation in our principal markets (8) changes in conditions in the credit and capital markets generally  including changes in borrower and counterparty creditworthiness (9) failures of banks falling under the scope of state compensation schemes (10) non- compliance with or changes in laws and regulations  including those concerning financial services  financial economic crimes and tax laws  and the interpretation and application thereof (11) geopolitical risks  political instabilities and policies and actions of governmental and regulatory authorities  including in connection with the invasion of Russia into Ukraine and the related international response measures (12) legal and regulatory risks in certain countries with less developed legal and regulatory frameworks (13) prudential supervision and regulations  including in relation to stress tests and regulatory restrictions on dividends and distributions (also among members of the group) (14) ING’s ability to meet minimum capital and other prudential regulatory requirements (15) changes in regulation of US commodities and derivatives businesses of ING and its customers (16) application of bank recovery and resolution regimes  including write down and conversion powers in relation to our securities (17) outcome of current and future litigation  enforcement proceedings  investigations or other regulatory actions  including claims by customers or stakeholders who feel misled or treated unfairly  and other conduct issues (18) changes in tax laws and regulations and risks of non-compliance or investigation in connection with tax laws  including FATCA (19) operational and IT risks  such as system disruptions or failures  breaches of security  cyber-attacks  human error  changes in operational practices or inadequate controls including in respect of third parties with which we do business and including any risks as a result of incomplete  inaccurate  or otherwise flawed outputs from the algorithms and data sets utilized in artificial intelligence (20) risks and challenges related to cybercrime including the eﬀects of cyberattacks and changes in legislation and regulation related to cybersecurity and data privacy  including such risks and challenges as a consequence of the use of emerging technologies  such as advanced forms of artificial intelligence and quantum computing (21) changes in general competitive factors  including ability to increase or maintain market share (22) inability to protect our intellectual property and infringement claims by third parties (23) inability of counterparties to meet financial obligations or ability to enforce rights against such counterparties (24) changes in credit ratings (25) business  operational  regulatory  reputation  transition and other risks and challenges in connection with climate change  diversity  equity and inclusion and other ESG-related matters  including data gathering and reporting and also including managing the conflicting laws and requirements of governments  regulators and authorities with respect to these topics (26) inability to attract and retain key personnel (27) future liabilities under defined benefit retirement plans (28) failure to manage business risks  including in connection with use of models  use of derivatives  or maintaining appropriate policies and guidelines (29) changes in capital and credit markets  including interbank funding  as well as customer deposits  which provide the liquidity and capital required to fund our operations  and (30) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING’s more recent disclosures  including press releases  which are available on www.ING.com.This document may contain ESG-related material that has been prepared by ING on the basis of publicly available information  internally developed data and other third-party sources believed to be reliable. ING has not sought to independently verify information obtained from public and third-party sources and makes no representations or warranties as to accuracy  completeness  reasonableness or reliability of such information.Materiality  as used in the context of ESG  is distinct from  and should not be confused with  such term as defined in the Market Abuse Regulation or as defined for Securities and Exchange Commission (‘SEC’) reporting purposes. Any issues identified as material for purposes of ESG in this document are therefore not necessarily material as defined in the Market Abuse Regulation or for SEC reporting purposes. In addition  there is currently no single  globally recognized set of accepted definitions in assessing whether activities are “green” or “sustainable.” Without limiting any of the statements contained herein  we make no representation or warranty as to whether any of our securities constitutes a green or sustainable security or conforms to present or future investor expectations or objectives for green or sustainable investing. For information on characteristics of a security  use of proceeds  a description of applicable project(s) and/or any other relevant information  please reference the offering documents for such security.This document may contain inactive textual addresses to internet websites operated by us and third parties. Reference to such websites is made for information purposes only  and information found at such websites is not incorporated by reference into this document. ING does not make any representation or warranty with respect to the accuracy or completeness of  or take any responsibility for  any information found at any websites operated by third parties. ING specifically disclaims any liability with respect to any information found at websites operated by third parties. ING cannot guarantee that websites operated by third parties remain available following the publication of this document  or that any information found at such websites will not change following the filing of this document. Many of those factors are beyond ING’s control.Any forward-looking statements made by or on behalf of ING speak only as of the date they are made  and ING assumes no obligation to publicly update or revise any forward-looking statements  whether as a result of new information or for any other reason.This document does not constitute an oﬀer to sell  or a solicitation of an oﬀer to purchase  any securities in the United States or any other jurisdiction.Attachment,neutral,0.41,0.58,0.01,mixed,0.11,0.13,0.75,True,English,"['share buyback programme', 'Progress', '2024 ING Group consolidated annual accounts', 'New York Stock Exchange', 'individual share purchase transactions', 'ING Groep N.V.', 'International Financial Reporting Standards', 'operating company ING Bank', 'ING Bank N.V.', '€2.0 billion share buyback programme', 'ING Group Investor Relations', 'currency exchange rates', 'international response measures', 'same accounting principles', 'global economic impact', 'interest rate levels', 'state compensation schemes', 'ESG index products', 'related international response', 'global financial institution', 'financial economic crimes', 'strong European base', 'Market Abuse Regulation', 'major market participant', 'ESG material risk', 'general economic conditions', 'particular economic conditions', 'related market disruption', 'daily repurchased shares', 'maximum total value', 'Frequent news updates', 'ESG risk rating', 'wholesale banking services', 'IMPORTANT LEGAL INFORMATION', 'ING Group shares', 'other forward-looking statements', 'ESG rating', 'share capital', 'Investor enquiries', 'financial services', 'low risk', 'financial markets', 'EU Regulation', 'European Union', 'financial information', 'ING website', 'ING operations', 'ING PROFILE', 'average price', 'total amount', 'weekly reports', 'total consideration', 'Press enquiries', 'INGA NA', 'INGA.AS', 'independent research', 'ratings providers', 'fifth year', 'Sustainalytics’ view', 'major sustainability', 'leading providers', 'FTSE Russell', 'low-carbon economy', 'sustainable activities', 'press release', 'IFRS- EU', 'Small differences', 'historical facts', 'future expectations', 'current views', 'unknown risks', 'actual results', 'customer behaviour', 'core markets', 'developing markets', 'fiscal uncertainty', 'United States', 'principal markets', 'capital markets', 'counterparty creditworthiness', 'geopolitical risks', 'political instabilities', 'regulatory authorities', 'detailed information', 'total number', 'tax laws', 'Raymond Vermeulen', '42,722 shares', 'Progress', '2 May', '25 August', '29 August', 'investorrelations', 'line', 'purpose', 'Note', 'editors', 'Newsroom', 'Photos', 'buildings', 'executives', 'download', 'Flickr', 'people', 'life', 'business', '60,000 employees', 'retail', 'customers', '100 countries', 'exchanges', 'Amsterdam', 'Brussels', 'ADRs', 'heart', 'policies', 'MSCI', 'AA', 'June', 'management', 'examples', 'Euronext', 'STOXX', 'Morningstar', 'Society', 'clients', 'lot', 'Elements', 'meaning', 'Article', 'accordance', 'document', 'figures', 'tables', 'rounding', 'limitation', 'assumptions', 'uncertainties', 'performance', 'events', 'factors', 'regional', 'invasion', 'Russia', 'Ukraine', 'default', 'discontinuation', 'benchmark', 'indices', 'inflation', 'deflation', 'borrower', 'failures', 'banks', 'scope', 'compliance', 'regulations', 'interpretation', 'application', 'governmental', 'connection', '18.0']",2025-09-02,2025-09-03,globenewswire.com
